A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Public ClinicalTrials.gov record NCT06948318. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time. Other aims are to learn how effective treatment with mezagitamab is and how the body processes it (called pharmacokinetics or PK) over a longer time. Participants of the following previous mezagitamab studies will be invited to join this continuation study: TAK-079-3002 and TAK-079-1004. In this continuation study, participants will receive mezagitamab when certain protocol criteria are met. During the study, participants will visit their study clinic several times.
Study identification
- NCT ID
- NCT06948318
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 13, 2025
- Primary completion
- Jul 28, 2029
- Completion
- Jul 28, 2029
- Last update posted
- Aug 13, 2026
2025 – 2029
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Genesis Cancer and Blood Institute - SCRI | Hot Springs | Arkansas | 71913 | Not yet recruiting |
| USC Norris Comprehensive Cancer Center - Keck Medicine of USC | Los Angeles | California | 90033 | Not yet recruiting |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | Withdrawn |
| Georgetown University Medical Center - Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20007 | Not yet recruiting |
| Emory University | Atlanta | Georgia | 30308 | Not yet recruiting |
| Innovative Hematology, Inc. | Indianapolis | Indiana | 46260 | Not yet recruiting |
| The University of Iowa | Iowa City | Iowa | 52242 | Not yet recruiting |
| University Of Louisville Brown Cancer Center | Louisville | Kentucky | 40202 | Not yet recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| University of Massachusetts Chan Medical School | Worcester | Massachusetts | 01655 | Not yet recruiting |
| MidAmerica Cancer Center | Kansas City | Missouri | 64132 | Not yet recruiting |
| American Oncology Partners of Maryland, PA | Morristown | New Jersey | 07960 | Not yet recruiting |
| Duke University Hospital | Durham | North Carolina | 27710 | Not yet recruiting |
| East Carolina University | Greenville | North Carolina | 27837 | Not yet recruiting |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program | Philadelphia | Pennsylvania | 19104 | Not yet recruiting |
| Lewis Katz School of Medicine at Temple University | Philadelphia | Pennsylvania | 19140 | Not yet recruiting |
| Baylor College of Medicine | Houston | Texas | 77030 | Not yet recruiting |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | Not yet recruiting |
| University of Washingto | Seattle | Washington | 98109 | Not yet recruiting |
| Versiti Wisconsin, Inc | Milwaukee | Wisconsin | 53226 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06948318, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06948318 live on ClinicalTrials.gov.